The oncology portfolio addresses major unmet needs in treatment direction and oncology therapeutics
- Polyclonal Antibody stimulator (“PAS”) induces the immune system to neutralize Gastrin 17, a primary pathway in Pancreatic and Gastric Cancer.
- Substantial clinical data demonstrates dramatic extension of survival time.
- Affiliation with Cato Research – a world-class oncology CRO.
- Funding completion of Phase 3 trials targeting drug approvals by 2019.
DiaTech ChemoIntel and ImmunoIntel
- DiaTech ChemoIntel and ImmunoIntel assay that directly measures tumor cell apoptosis.
- Unique platform provides oncologists the ability to “personalize” chemotherapy and immunotherapy selection across most cancer types.
- Targeting EU and U.S. launch in Breast and Ovarian Cancer by 2019.
- Europe-based biotech company that is developing T-cell based immunotherapies (therapeutic cancer vaccines).
- Developing fixed combinations of immunotherapy-based cancer treatments to overcome the immuno-suppressive environment surrounding cancer cells and to target specific tumors.
- Investment needed to fund the development program through Phase IIa, which with success is projected to represent substantial value inflection.
- This new technology is designed to prevent cancers from metastasing by using Voltage-gated sodium channel (VGSC) inhibitors that are already approved and now have been re-purposed by Celex.
- The core drugs for this use are known to be safe; clinical trials are required to optimise the dose and prove efficacy.
- The market potential of such a drug is enormous and could reasonably be predicted to be one of the biggest selling drug groups of all time.